



Huons Global

Investor Relations

2022. 1Q



Huons Global

Disclaimer

All information in this book including business performance and financial report is written by Korean-International Financial Reporting Standards(K-IFRS) .

This book includes a “forecast” about future. It is not about the past, but the future business plan including expected management status and financial performance, and sometimes there can be word such as ‘anticipation’, ‘forecast’, ‘plan’, ‘expectation’, and ‘(E)’.

A “forecast” often means uncertain factors which can affect the company either positively or vice versa, and those can include:


- Domestic or international financial market trends including fluctuation of foreign exchange rate or interest rate.
- Company’s very important strategic decision such as M&A
- Unexpected business environment change in the main industry
- Other internal and external change that can affect the company’s management and finance.

Because of those uncertain risks, company’s actual business performance can be different from the “forecast” in this booklet. Also the information we provide is written as of the day we deliver the presentation, so it can be changed due to unexpected external status of industry or internal company’s revision of strategies without any prior notice in the future.

Contents

- 1 Introduction**
- 2 Business Results**
- 3 Subsidiaries**
- 4 Financial Statements**

“Total Healthcare Group”
Includes Pharma, Medical Device, Health Functional Food and Cosmetic business



※ HuM&C will merge with Hubena on July 1st

Business Overview

- ✓ Group Vision : **Total Healthcare Group**
- ✓ Group Strategy : **Open Innovation & In-house R&D**
- ✓ By merging subsidiaries, plan to specialize in Health Functional Food, Medical Device and Healthcare subsidiary material business



Pharma Bio-Pharma	Huons, Humedix, Huons Bio Pharma, Huons Meditech, Huons Lab
Medical Device	Huons, Humedix, Huons Meditech,
Health Functional Food	Huons, Huons Foodience
Container & etc	HuM&C, Hubena, HUONS USA, Blossom Story, Blossom Pictures



Board Members

		Soo-Young Song	Sung-Tae Yoon	WanSeop Paul Kim	Kyu-Yeon Lee	Byung-Hun Tak	Jin-Woo Chang
Position		President C.E.O	Chairman	President	Director Outside Director	Director Outside Director	Director Outside Director
P r o f i l e	Current	C.E.O. of Huons Global and Huons	Board Chairman of KPBMA (Korea Pharmaceutical and Bio-Pharma Manufacturers Association)	Director of Huons Global CEO of HuonsLab	Advisor of law firm Lee&Ko	-	Director of YonSei Univ. Brain Research Institute
	Recent & Past	C.E.O. of Deloitte Consulting Korea C.E.O of Deloitte Consulting Japan Senior Vice President of PwC Japan	C.E.O of Huons Global IBM Korea MS Project Mgt. at Hanyang Univ.	BMS/GSK/Diosynth MIT Scientist PhD Biology at Korea Univ. MSc Molecular Biology in CANADA	Managing Director of Korea Exchange (KRX)	Commander of Seoul Police Department BS Fine Chemistry at Seoul National Univ. of Science & Technology	Professor of YonSei Univ. College of Medicine M.D., PH.D.

Audit Committee

Chairman Kyu-Yeon Lee

Member Byung-Hun Tak

Member Jin-Woo Chang

ESG Committee

Chairman Soo-Young Song


Member Kyu-Yeon Lee

Member Jin-Woo Chang

Company Overview

- ✓ Consolidated sales CAGR 15.7%, operating income CAGR 4.2% since 2016
- ✓ Converted to a holding company in 2016, and now has 7 subsidiaries and 4 sub-subsidiaries
- ✓ Spun off the bio business division in April 2021, and became a pure holding company

(Consolidated, billion KRW)




Capital Allocation Plan – Investment for growth

Strengthen investment to continue growth

- ✓ Strengthening In-house R&D & Seeking Open-Innovation.
- ✓ Finding new business items through License In/Out, Strategic Investment.
- ✓ **After converting to a pure holding company, Huons Global will lead investment in new business areas.**

Key Investment Status (Huons Group)

Classification	Cases	Remarks
Pharma	14	Biosimilar, injection, API, Etc.
Medical device	7	Dental, Diabetes
Etc.	5	drug development platform based on AI






[Sales] 1Q 159.7 B KRW (YoY ▲ 21.3%, QoQ ▲ 0.3%)

[Profit] 1Q OP 20.7 B KRW (YoY ▲ 21.3%, QoQ ▲ 0.3%), 1Q NP 12.8 B KRW (YoY ▼ 18.6%, QoQ turn to profit)


Sales

[Unit : billion KRW]




Operating Profit

[Unit : billion KRW]



Net Profit

[Unit : billion KRW]





Consolidated Performance increased due to the stable growth of major corporates.

(Unit : Million KRW)

Corporate	Sales			Operating Profit			Net Profit		
	1Q 22	1Q 21	YoY	1Q 22	1Q 21	YoY	1Q 22	1Q 21	YoY
Huons Global (Consolidated)	159,673	131,643	21.3%	20,674	20,542	0.6%	12,803	15,723	-18.6%
Huons Global	11,237	14,617	-23.1%	5,752	6,708	-14.2%	4,267	6,726	-36.6%
Huons	108,716	89,885	21.0%	11,552	12,217	-5.4%	8,861	8,506	4.2%
Huons Foodience	8,643	11,305	-23.5%	-181	533	Run a deficit	-257	381	Run a deficit
Humedix	25,384	21,696	17.0%	4,085	2,648	54.3%	11,167	2,453	355.2%
HuM&C	3,103	-	-	-120	-	-	268	-	-
Hubena	6,559	5,933	10.6%	590	543	8.7%	432	439	-1.7%
Huons Meditech	17,504	16,187	8.1%	3,025	3,050	-0.8%	2,997	2,636	13.7%
Huons Biopharma	4,278	-	-	496	-	-	599	-	-

1) The performance of subsidiaries is based on separate financial statements before removing internal transactions.

2) The performance of '22. 1Q Huons Meditech includes Huons Medical's January's performance, and '21. 1Q is the combined of Huons Medicare and Huons Medical.

3) The performance of '22. 1Q Huons Foodience is the combined performance of Huons Nature and Huons Natural.

4) HuM&C, Blossom Story and Blossom Pictures were incorporated into subsidiaries on '21. 2Q.



Financial Status

[Unit : million KRW]

Classificaton	FY2020	FY2021	1Q22	YTD
Assets	949,023	1,283,748	1,297,494	+13,746
Current assets	427,322	618,519	606,188	-12,332
- cash etc.	225,421	373,150	351,837	-21,313
Non-current assets	521,700	665,228	691,306	+26,078
Liabilities	293,624	432,627	449,124	+16,497
Current liabilities	237,373	347,001	358,401	+11,399
Non-current liabilities	56,251	85,626	90,724	+5,098
-Total borrowings	147,643	140,189	152,341	+12,153
Equity	655,399	851,120	848,369	-2,751

※ cash etc. : cash + cash equivalents + short-term deposits

Financial Ratio



※ Borrowings ratio = (total borrowings / equity)

Based on Pharma(ETC), stably growing through expansion of related businesses

Pharma(ETC)

- Medications that require prescription
- Comprehensive portfolio covering various fields
- Expanding markets(export local anesthetics to the U.S)



Beauty·Well-being·Others

- Medications and others for health maintenance
- Health Functional Food and Medical Device



CMO

- Produce multiple items(eye drops, injections, etc)
- Customers : Multiple domestic and foreign pharmaceutical companies



Growth Strategy "Open Innovation"

- Make an exclusive domestic sales rights contracts and Joint research agreements
- Aim to find a next-generation growth-engine through Open Innovation

Classification	Indication	Status
New Chemical Entities	Liver disease	Selection of candidate materials in 2023
	Heart failure	Planning to start non-clinical in 2022
	Ocular disease	Planning to start IND in 2023

Subsidiary "Huons Foodience"

- Health functional food company
- Business in OEM/ODM, Own brand and export
- Building Value chain from raw materials to logistics
- Continuous development in raw materials

Stably growing based on Aesthetic and Pharmaceutical products using HA·PDRN

Filler

- Used for beauty and healthcare such as wrinkle improvement
- Registered in China and Europe



Pharma·CMO

- ETC based on API, Manufacturing PFS, Amp, Vial, Eye drops
- Launched 1 shot arthritis(2nd in Domestic), L/O to China, EU CE certification



Cosmetics·etc.

- Functional cosmetics using HA·PDRN, Achieved approval in China
- Launched LIZTOX('19.06)



Growth Strategy "Biosimilar APIs"

- Strengthening aesthetic portfolio and becoming Bio-specialized company by expanding biosimilar API business

Classification	DMF Approval	Remarks
HA	2008	Raw material : Filler, injection of arthritis, eyedrops
PDRN	2018	Raw material : Regenerative medicine and beauty
Heparin	2022	First in localizing animal origin API
Hyaluronidase	2022	Less side effects

Cosmetic packaging and Medical container(Ampulem, Vial, Cartridge)

- Incorporate Hubena into a subsidiary ('22.04), merged('22.07) to diversify business area
- Aiming for Healthcare Total Subsidiary Material company
- Work with affiliates to increase profitability and secure growth momentum

Cosmetic Packaging

- Manufacture puff, sponge, container for make-up
- Supplying materials to cosmetics companies(domestic&foreign)



Medical container

- Manufacture medical glass containers through special glass technology
- 120 clients including Huons Group



Physical and chemical equipment distribution

- Merged chemical equipment distribution business
- Distribute by establishing regional agencies and online malls



Healthcare Total Subsidiary Material company

Conduct Biological Pharma business include botulinum toxin

- Bio business division was spun off from Huons Global('21.04)
- Attracted 155.4 billion KRW investment from IMEIK(China) ('21.06)
- Share Holding Ratio('21.09) : Huons Global(74.6%), IMEIK(25.4%)

Manufacturing Facilities	Product line-up	
	HUTOX(export)	Liztox(domestic)
<ul style="list-style-type: none"> Facilities in Jecheon <ul style="list-style-type: none"> Plant 1(1 mil Vials) Plant 2(5 mil Vials) Plant 3(9 mil Vials) : complete till 2024, operate in 2025 Selected as an institution of merit for biosafety management('20.10) 	<ul style="list-style-type: none"> Approval for export('16.10) 32 countries, 26 partner contracts License and Supply Agreement with AQUAVIT HOLDINGS in US('21.04) License and Supply Agreement with HAEMATO PHARM in EU('21.10) → Planning Clinical trial 	<ul style="list-style-type: none"> Launched('19.06) Co-sales in domestic market : Huons and Humedix 50unit('21.06), 100unit('19.04), 200unit('21.07) approved







R&D status

- Expansion of indications and development of small molecule formulations

Pipe-line	Indications	Discovery	Pre-clinical	Phase I	Phase II	Phase III	Registration
HBPB1-001 (900kDa)	Glabellar lines						●
	Crow's feet lines						●
	Post stroke-upper limb spasticity					●	
	Benign masseteric hypertrophy				●		
HBPB1-002 (150kDa)	Glabellar lines				●		
HBPB1-004	Glabellar lines	●					
HBPB1-005	Glabellar lines	●					
HBPB3-003	Cellulite	●					

Manufacture medical disinfectors, disinfectants and sterilizers

- Established Huons Meditech : Merged Huons Medicare and Huons Medical ('22.02)
- Portfolio of medical devices(Beauty, Therapy, Sterilizers, etc.)

Antiseptic and Pharma(ETC)	Medical Device			
	Medical Sterilizers	Space Sterilizers	Beauty	Therapy
<ul style="list-style-type: none"> ▪ Antiseptic products for artificial kidney, endoscope instrument sterilization, body/hands tissue, and etc. ▪ Eyedrops, ETC for dyslipidemia and digestive system etc. 	<ul style="list-style-type: none"> ▪ 'Huen Single' ▪ "single use and discard" system ▪ Target on general hospital and overseas market 	<ul style="list-style-type: none"> ▪ 'HUEN IVH ER' Europe CE certification 	<ul style="list-style-type: none"> ▪ 'Derma Shine' for Autsko-Injection (China NMPA, Europe CE, Austrailia TGA certification) ▪ 'Derma AKNE' for acne treatment (Europe CE certification) 	<ul style="list-style-type: none"> ▪ Extracorporeal shockwave therapy 'URO-EMX', 'URO-EX', 'IMPO 88' ▪ 'JILL'SOF' for Vaginal dryness 

To become Medical device company covers various fields

Subsidiary specialized in R&D of Biopharmaceuticals

- Hold 6 types of biological drugs pipelines
- Research and develop new peptide and recombinant protein medicines intensively

Group	Indication	Discovery	Pre-Clinical
New Biological Drug	Metabolism (Short Bowel Syndrome)	HLB1-001	4Q, 22
	Fibrosis(Skin)	HLB1-002 (Drug Delivery)	3Q, 22
		HLB1-003	1Q, 23
		HLB1-005	2Q, 23
Biosimilar	Osteoporosis	HLB3-001	1Q, 23



■ Consolidated Statement of Financial Position

[Unit : million
KRW]

Classificaton	FY2020	FY2021	1Q22
Assets	949,023	1,283,748	1,297,494
Current assets	427,322	618,519	606,188
Non-current assets	521,700	665,228	691,306
Liabilities	293,624	432,627	449,124
Current liabilities	237,373	347,001	358,401
Non-current liabilities	56,251	85,626	90,724
Equity	655,399	851,120	848,369
Equity attributable to owners of parent	412,828	537,838	538,763
Issued capital	5,732	6,015	6,311
Capital surplus	247,877	374,578	378,678
Capital adjustments	-25,323	-26,605	-29,432
Other comprehensive income accumulated	409	539	520
Retained earnings	184,132	183,311	182,687
Non-controlling interests	242,570	313,282	309,606
Total equity and liabilities	949,023	1,283,748	1,297,494



■ Consolidated Statement of Comprehensive Income

[Unit : million
KRW]

Classificaton	1Q21	2Q21	3Q21	4Q21	1Q22
Sales	131,643	143,711	145,427	159,156	159,673
Cost of sales	111,101	124,218	126,311	144,964	138,999
Operating Profit	20,542	19,493	19,116	14,191	20,674
Gains/Losses on investments in associates	-400	52	-21	-2,895	591
Other gains/losses	-494	-1,552	16,197	-21,728	-2,304
Profit before tax	19,649	17,993	35,292	-10,431	18,370
Income tax expense	3,925	3,846	20,525	2,135	5,566
Net Profit	15,724	14,147	14,766	-12,566	12,803
Profit, attributable to owners	7,306	6,551	4,447	-14,309	5,588
Profit, attributable to non-controlling interests	8,418	7,596	10,320	1,742	7,216
Earnings per share	617	554	376	-1,209	450

Thank you